Can biotechs be 'catfished'? AIM ImmunoTech hits back at online identity thief
19 Jul 2023
Phase 2Immunotherapy
Preview
Source: FierceBiotech
As of early Wednesday morning, the LinkedIn profile had been removed.
Being “catfished”—a term for impersonating someone else online, usually to lure a romantic partner—has long been a problem in the shadowy world of social media. But not even biotechs are immune from the phenomenon of identity theft, as AIM ImmunoTech learned this week.
The drug developer recently discovered that an “unknown person(s) and/or organization(s)” had set up a LinkedIn profile “claiming to represent AIM ImmunoTech Europe” and was “using the company’s name without authorization.”
The profile, which claimed to be linked to an organization called Clavinvest, had been “promoting misinformation related to AIM’s ongoing clinical activities,” the biotech said in a postmarket release Tuesday.
The “unauthorized and unaffiliated profile” had used “AIM’s logo and copyrighted imagery to provide the impression that it has a formal relationship with AIM concerning AIM’s activities with Erasmus Medical Center in the Netherlands and Prof. C.H.J. van Eijck.”
AIM’s antiviral and immuno-modulator drug Ampligen is undergoing a phase 2 trial for pancreatic cancer at Erasmus Medical Center. Casper van Eijck, M.D., Ph.D., is a surgeon at the center who co-authored a recent paper assessing Ampligen’s effectiveness as an anti-tumor drug.
AIM added in the release that it was “taking all of the necessary actions to remove and eliminate this unauthorized activity.” As of early Wednesday morning, the LinkedIn profile had been removed.
Fierce Biotech has contacted AIM ImmunoTech for more details about the incident.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.